An interventional study of CIPN assessment and EV blood analysis in Chemotherapy-Induced Peripheral Neuropathy, Breast Cancer and Gastrointestinal Cancer, sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Not applicable, Interventional, and Diagnostic
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 887 studies in Breast Neoplasms with a site in Italy — 231 open to participants now, 350 under way, 86 of them phase 3. Breast Neoplasms · Italy.
Among the 887 studies in Breast Neoplasms with a site in Italy, this one is the 443rd largest by planned enrollment of the 687 interventional ones that give a count, is one of 62 that started in 2025, is one of 161 with no phase, reaches primary completion later than 153 of the 349 other live ones, and was the 851st registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →231 of the 887 studies in Breast Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Italy, United States, Belgium and 5 more countries
Ages 18+
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 18+ · Women only
UNICANCER · Sites in Italy, Belgium, France and 4 more countries
Ages 35–45 · Women only
Massimiliano Bortolini · Sites in Italy
Ages 18–75 · Women only
AstraZeneca · Sites in Italy, United States, France and 6 more countries
Ages 18–130
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
887 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 84 · Phase 2 235 · Phase 3 239 · Phase 4 13
First in 1993; this study’s year is marked. 62 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 208 across the 687 interventional studies, 256 across the 195 observational. Of the 458 that completed or were terminated, 222 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
417 of 887 have an industry lead sponsor. The 10 most frequent:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico is the lead sponsor of 237 studies on the registry; 81 are open to participants now.
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico has 3 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
81 of the studies in Breast Neoplasms with a site in Italy that are under way reach primary completion within a year, 20 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03820830Phase 3ETOP IBCSG Partners FoundationPalbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer | 2026-12 |
| NCT03595592Phase 3Fondazione MichelangeloNeoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer | 2026-12-15 |
| NCT05909397Phase 3PfizerVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | 2026-12-30 |
| NCT06611514Phase 3European Institute of OncologyEffect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer | 2027-01-01 |
| NCT05038735Phase 3Novartis PharmaceuticalsStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | 2027-01-28 |
Add all 81 to your calendar (.ics) → With an account.
Among the 887 studies in Breast Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether extracellular vesicles (EVs) in the blood can be used as biomarkers to predict chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer patients receiving chemotherapy with taxanes, platinum compounds, or antimitotic drugs. The main questions the study aims to answer are whether blood levels of EVs change in patients who develop CIPN during and after chemotherapy and whether specific features of EVs, including lipids and microRNAs, are associated with the development and severity of CIPN. Participants will be followed from before the start of chemotherapy until six months after treatment ends to evaluate how changes in EVs relate to nerve damage caused by chemotherapy. During the study, participants will provide blood samples before chemotherapy, at the end of treatment, and six months later for measurement and molecular analysis of EVs, will complete questionnaires about neuropathy symptoms, and will undergo simple, non-invasive nerve function tests using a tuning fork (diapason) and a Neuropen device. This study does not test cancer drugs; instead, it aims to identify biological markers in blood that may help predict which patients are at higher risk of developing CIPN, with the goal of improving monitoring and care during cancer treatment.
CIPN is a frequent and often long-lasting complication of treatment with several commonly used antineoplastic agents, including taxanes, platinum compounds, and antimitotic drugs. The condition primarily affects sensory neurons of the dorsal root ganglia and peripheral nerve fibers, leading to symptoms such as numbness, tingling, pain, and loss of vibration or tactile sensation. The severity and persistence of CIPN vary markedly between individuals, and currently there are no validated biological markers that allow early identification of patients at increased risk or objective monitoring of neurotoxicity during treatment. As a result, CIPN is usually detected only after clinical symptoms appear, at a stage when nerve damage may already be established and difficult to reverse.
EVs are membrane-bound particles released by virtually all cell types and present in large numbers in biological fluids, including blood. They contain proteins, lipids, and nucleic acids that reflect the physiological and pathological state of their cells of origin. Because EVs can originate from neural and glial cells and can cross biological barriers, they provide a potential window into otherwise inaccessible tissues such as the peripheral nervous system. Changes in EV concentration, membrane composition, and RNA cargo have been reported in several neurological and neurodegenerative conditions, supporting their potential role as circulating indicators of neuronal injury and dysfunction.
This study is designed to evaluate whether longitudinal changes in circulating EVs are associated with the development of CIPN in patients undergoing chemotherapy. Blood samples collected at predefined time points will be used to isolate and quantify EVs and to characterize selected molecular components of their cargo, including membrane lipids and microRNAs. These EV-based measurements will be evaluated in relation to standardized clinical and neurophysiological assessments of peripheral neuropathy performed over the course of treatment and follow-up. By integrating biological and clinical data, the study aims to explore whether EV-derived markers reflect early neurotoxic effects of chemotherapy and whether they may capture individual susceptibility to CIPN.
The study uses a single-group, longitudinal design in which each participant serves as their own reference over time. This approach allows the evaluation of intra-individual changes in EV-related parameters across the different phases of chemotherapy exposure and recovery. It is particularly suited for biomarker discovery in conditions such as CIPN, where baseline inter-individual variability is high and where the key biological signal of interest is the change from an individual's pre-treatment state. This design also avoids the need for a concurrent untreated control group, which would not be ethically or clinically appropriate in this setting.
EVs will be isolated from plasma using standardized protocols designed to preserve vesicle integrity and minimize contamination from non-vesicular particles. Quantitative analysis will be performed to determine the concentration of circulating EVs, expressed as vesicles per microliter, at each study time point. In addition, qualitative analyses will be carried out to investigate specific components of EV cargo that may be relevant to nerve injury and inflammation. These include selected classes of membrane lipids, such as phosphatidylcholine, sphingomyelin, and cholesterol, which are known to influence membrane stability and signaling, as well as microRNAs involved in neuronal function, stress responses, and neuroinflammatory pathways. The combination of quantitative and molecular profiling is intended to provide a multidimensional view of EV dynamics in relation to chemotherapy exposure.
Clinical evaluation of CIPN will be performed using validated symptom-based questionnaires and objective bedside tests of peripheral nerve function. These assessments capture both patient-reported experience and physician-based measures of sensory impairment, allowing a more comprehensive characterization of neurotoxicity than either approach alone. By relating EV-based measurements to these clinical data over time, the study will explore whether changes in EV concentration or composition precede, accompany, or follow the onset of neuropathic symptoms.
Individual susceptibility to CIPN is influenced by multiple factors, including demographic characteristics, pre-existing neuropathy, and genetic background. Although the primary focus of this study is on EV-derived biomarkers, relevant clinical and demographic information will be collected to allow exploratory analyses of how these factors may interact with EV patterns. This will help to distinguish EV changes that are primarily driven by chemotherapy-induced nerve damage from those that reflect underlying patient-specific characteristics.
Because the study does not modify or assign cancer treatments, all oncologic care will proceed according to standard clinical practice. The additional procedures introduced by the study are limited to blood sampling and non-invasive neurological assessments. These procedures are intended solely to support biomarker analysis and phenotypic characterization of CIPN and are not expected to interfere with therapeutic decisions or outcomes.
By focusing on EVs as circulating indicators of peripheral nerve injury, this study aims to generate data that may support the future development of minimally invasive tools for monitoring neurotoxicity in patients receiving chemotherapy. If specific EV-based patterns are found to be associated with CIPN, this could open the way to earlier identification of at-risk individuals and to more personalized management of neurotoxic side effects, with the ultimate goal of improving quality of life for cancer survivors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients eligible to receive antineoplastic compounds with taxanes, platinum compounds, or antimitotic agents, evaluated before the start of chemotherapy (baseline).
Procedure: CIPN assessment · Other: EV blood analysis
Patients who have completed the planned chemotherapy cycles with taxanes, platinum compounds, or antimitotic agents and are evaluated at the end of treatment.
Procedure: CIPN assessment · Other: EV blood analysis
Patients evaluated six months after completion of chemotherapy.
Procedure: CIPN assessment · Other: EV blood analysis
Assessment of CIPN using a combination of physician-based and patient-reported measures. Objective evaluation includes assessment of vibration sensitivity. Patient-reported symptoms are assessed using the EORTC-CIPN20 questionnaire (Italian version), a 20-item self-administered questionnaire completed in approximately 10 minutes.
Collection of blood samples for isolation, quantification, and molecular characterization of circulating EVs, including analysis of membrane lipid composition and microRNA content.
This study also gives Enfortumab vedotinStudies of Enfortumab vedotinEnfortumab vedotin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Change from Baseline in Circulating EV Concentration
Change in the concentration of circulating extracellular vesicles, expressed as vesicles per microliter of plasma, measured by comparing values at the end of chemotherapy (T1) and 6 months after completion of treatment (T2) with baseline at initiation of chemotherapy (T0), in relation to the development of chemotherapy-induced peripheral neuropathy. T1 corresponds to 5 months. T2 corresponds to 6 months after completion of treatment.
Time frame: 11 months from enrollment (T0), to completion of chemotherapy (T2)
Change from End of Chemotherapy in Circulating EV Concentration
Change in the concentration of circulating extracellular vesicles, expressed as vesicles per microliter of plasma, measured by comparing values at the end of chemotherapy (T1) and 6 months after completion of treatment (T2) with baseline at initiation of chemotherapy (T0), in relation to the development of chemotherapy-induced peripheral neuropathy. T1 corresponds to 5 months. T2 corresponds to 6 months after completion of treatment.
Time frame: 11 months from enrollment (T0), to completion of chemotherapy (T2)
Changes in EV Membrane Lipid Composition
The relative abundance of major EV membrane lipid classes-phosphatidylcholine, sphingomyelin, and cholesterol-will be quantified using targeted lipidomic analysis (e.g., mass spectrometry-based lipid profiling). Lipid levels will be expressed as mol (%) within EV samples collected at T0 (baseline), at the end of chemotherapy (T1 corresponding to 5 months) and at T2 (corresponding to 6 months after completion of treatment). Changes in lipid composition over time will be summarized descriptively and compared among time points (T1 vs T1 and T0 vs T2) to assess chemotherapy-associated alterations in EV membrane lipid profiles.
Time frame: 11 months from enrollment (T0), to completion of chemotherapy (T2)
Changes in Extracellular Vesicle microRNA Profile
Changes in the microRNA content of circulating extracellular vesicles measured at T0 (baseline), at the end of chemotherapy (T1 corresponding to 5 months from the initiation of chemotherapy) and at the end of chemotherapy (T2).
Time frame: 11 months from enrollment (T0), to completion of chemotherapy (T2)
Started Jan 2025 (actual). Primary completion is estimated for Sep 2026, 20 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 20 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico →